Primiparous cows received 29 mg of bovine growth hormone (bGH)/d, or 12 mg of bovine growth hormone-releasing factor (bGHRF)/d by continuous i.v. infusion, or no treatment (controls) from 118 to 181 d postpartum. Compared with controls, bGHRF and bGH did not influence the amount of erythrocyte-type glucose transporter (GLUT1) protein in the mammary gland; however, GLUT1 mRNA was increased ( P < .01) by bGHRF, but not by bGH. The insulin-responsive glucose transporter (GLUT4) mRNA in skeletal muscle was decreased by 44% ( P < .05) as a result of bGH treatment, but there was no significant effect of bGHRF. The GLUT4 mRNA was barely detectable in the omental fat of control cows and became undetectable in bGH-and bGHRF-treated cows. The results of the present study indicate that bGH and bGHRF may increase glucose availability to the mammary gland by regulating glucose transporter expression in skeletal muscle and omental fat. Our data also indicate that the galactopoietic action of bGHRF may not be mediated solely through GH.
Introduction
Administration of bovine growth hormone ( bGH) and bGH-releasing factor ( bGHRF) to dairy cows increases milk yield (Dahl et al., 1990; Bauman and Vernon, 1993; Burton et al., 1994; Binelli et al., 1995) . The augmented production associated with exogenous bGH and bGHRF administration increases the animal's requirement for milk precursors and energy substrates. However, bGH treatment does not alter the digestibilities of dietary dry matter, energy, and nitrogen in lactating ruminants (Eisemann et al., 1986; Tyrrell et al., 1988 ). Short-term bGH treatment ( 1 to 3 wk) increases milk yield without a concomitant increase in feed intake (Bauman and McCutcheon, 1986 ). Thus, increased milk yield in response to bGH treatment requires repartitioning of nutrients to accommodate the increase in rates of milk synthesis, perhaps at the expense of maintenance and(or) growth of other tissues. For example, GH decreases glucose uptake in skeletal muscle and adipose tissues (Davidson, 1987; McDowell et al., 1987) , whereas it increases glucose uptake in the mammary gland (Davis et al., 1988a; Fullerton et al., 1989) .
During lactation, lactose synthesis from glucose in the mammary epithelial cells seems to be the ratelimiting step in milk synthesis (Neville et al., 1983) . In many mammalian cells, a major point of metabolic regulation of glucose utilization is the transport of glucose across cell membranes, which is mediated by a family of tissue-specific facilitative glucose transporters (Kahn, 1992) . Mammary gland mainly expresses GLUT1 glucose transporter protein (Madon et al., 1990; Zhao et al., 1993; , whereas muscle and fat primarily express GLUT4 (Zhao et al., 1993) .
To address our hypothesis that GH may regulate glucose partitioning by influencing the amount of glucose transporters in various tissues, we examined the gene expression of glucose transporters in the mammary gland, skeletal muscle, and omental fat of lactating cows receiving continuous i.v. infusions of bGH and bGHRF. Data on lactation performance and serum hormone concentrations have been reported by Binelli et al. (1995) and Vanderkooi et al. (1995) .
Materials and Methods

Animals and Tissues
Thirty primiparous Holstein cows, Bos taurus, were used in a split block design with cows allocated by date of parturition into 10 blocks. Within each block, three cows were randomly assigned to receive continuous i.v. infusions of bGH (29 mg/d; Somavubove, The Upjohn Co., Kalamazoo, MI), bGHRF (12 mg/d; Upjohn), or no treatment (controls) for 63 d, commencing 118 d after parturition . Doses selected were based on previous experiments (Dahl et al., 1993) , in which these same doses elicited similar increases in serum GH concentrations. Cows were fed a total mixed diet for ad libitum intake. Cows within a block were slaughtered on d 63 of treatment. Samples of mammary gland, skeletal muscle (Pectoralis prefundis), and omental fat were obtained immediately after slaughter. The samples were frozen in liquid nitrogen and stored at −75°C as described previously (Zhao et al., 1993) . Three blocks of animals were randomly used in this study.
Northern Blotting
Total RNA was isolated from tissue samples with a guanidinium thiocyanate-CsCl procedure (Chirgwin et al., 1979) . Total RNA (30 mg ) was electrophoresed on denaturing 1% agarose/.66 M formaldehyde gels and transferred to nylon membranes (Bio-Rad, Richmond, CA) by capillary diffusion. The integrity and relative amounts of RNA were assessed with UV-light visualization of ethidium bromide-stained RNA. Membranes were prehybridized for 2 h at 50°C in a medium containing 60% (vol/vol) formamide, 1× SSPE (.18 M NaCl, .01 M sodium phosphate at pH 7.4, and 1 mM EDTA), .5% (wt/vol) nonfat dried milk (Carnation Ltd., Ontario, Canada), 10% (wt/vol) dextran sulfate, 1% (wt/vol) SDS, 500 mg/mL of salmon testes DNA, and 200 mg/mL of yeast tRNA. After prehybridization, hybridization was carried out for 16 to 18 h at 50°C in fresh buffer containing 32 P-labeled riboprobes ( 1 × 10 6 cpm/mL) generated as previously described (Zhao et al., 1993) . Membranes were then rinsed briefly in 2× SSC ( 1 × SSC is .15 M NaCl and .015 M sodium citrate at pH 7.0), washed for 15 min at 22°C in 2× SSC containing .1% SDS, washed at 70°C in .2× SSC containing 1% SDS, and rinsed briefly in .2× SSC. Autoradiography was performed at −70°C with an intensifying screen and quantified with scanning densitometry (Imaging Densitometer GS-670; Bio-Rad).
Preparation of Crude Membrane Fractions
Membrane fractions were prepared by homogenization of the tissue in 10 volumes of ice-cold .25 M sucrose, 1 mM EDTA, 10 mM Tris·HCl (pH 7.4), 1 mg/ mL of aprotinin, and 1 mM phenylmethylsulfonyl fluoride, with a Brinkman Polytron homogenizer. Homogenates were centrifuged for 10 min at 1,000 × g (Beckman J2-21 centrifuge with a JA-14 rotor; Beckman, Somerset, NJ), and the supernatant was centrifuged for 45 min at 13,000 × g (with JA-14 rotor). The cytosol was then centrifuged for 1 h at 100,000 × g (with a Sorvall T647.5 rotor; Sorvall, Wilmington, DE), and the membrane pellet was resuspended in the homogenization buffer. Protein concentration was measured with the Bradford dyebinding procedure (Bio-Rad Protein Assay), using BSA as the standard.
Primary Antibody
The primary antibody was purchased from East Acres Biologicals (Southbridge, MA). The anti-GLUT1 was raised against a synthetic peptide corresponding to the 11 amino acids in the carboxyl terminus of rat brain glucose transporter; the same 11 amino acid peptide sequence is also present in bovine GLUT1 (Boado and Pardridge, 1990) . The GLUT1 antiserum detected strong signals in rat brain and bovine mammary gland, but not in bovine liver and skeletal muscle .
Western Blotting
Membranes were resuspended in Laemmli sample buffer (Laemmli, 1970) and resolved on 12% SDS-PAGE using a Mini-protein II Electrophoresis Cell (Bio-Rad). The proteins were electrophoretically transferred to nitrocellulose filter (BA 85; Schleicher and Schuell, Dassel, Germany). Protein markers (Rainbow markers; Amersham, Arlington Heights, IL) were used as molecular mass standards and to assess the efficiency of the transfer. The blot was blocked overnight at 4°C in TBS (20 mM Tris [pH 7.4] and 137 mM NaCl) containing 5% nonfat dried milk and incubated for 1.5 h at room temperature in TBS, .5% nonfat dry milk, with a 1:200 dilution of GLUT1 antiserum. The filter was then washed twice at room temperature for 15 min in TBS and incubated for 1 h at room temperature in TBS, .5% nonfat dried milk, with a 1:2,000 dilution of goat anti-rabbit lgG conjugated to horseradish peroxidase (Calbiochem, La Jolla, CA). The immune complex was detected using the Amersham ECL Western blotting system following the manufacturer's instructions. The blot was autoradiographed (Hyperfilm ECL; Amersham) and Table 1 . Mean abundance (densitometric units) of GLUT1 mRNA in mammary gland, GLUT1 protein in mammary gland, and GLUT4 mRNA in skeletal muscle of cows receiving no treatment (Ctrl), 29 mg of bGH/d, or 12 mg of bGHRF/d a a GLUT1 = the erythrocyte-type glucose transporter; GLUT4 = the insulin-responsive glucose transporter; bGH = bovine growth hormone; bGHRF = bovine growth hormone-releasing factor. Figure 1 . Northern blot analysis of erythrocyte-type glucose transporter (GLUT1) mRNA from mammary glands of bovine growth hormone (bGH)-and bovine growth hormone-releasing factor (bGHRF)-treated cows and control cows. GHRF = RNA from bGHRF-treated cows; CTRL = RNA from control cows; GH = RNA from bGH-treated cows. The autoradiogram was exposed for 70 h. 
P-values
Statistical Analysis
The significance of differences between mean values for variables measured were assessed using ANOVA for paired data.
Results and Discussion
Influence of bGH and bGHRF on GLUT1 mRNA and Protein in the Mammary Gland
Administration of bGHRF for a 63-d period resulted in a 21% increase in GLUT1 mRNA ( P < .01) in the mammary gland (Figure 1 ; Table 1) , as judged by quantitative densitometry. However, the amount of GLUT1 protein in the crude mammary membrane preparation was not affected by bGHRF treatment (Figure 2 ; Table 1 ). Neither the amount of GLUT1 mRNA nor GLUT1 protein concentration was changed by bGH treatment (Figures 1 and 2 ; Table 1 ).
Administration of bGH and bGHRF increased the milk yield of cows in this study by 17 and 14%, respectively ; thus, substrate requirements for milk precursors and energy were increased. Our data indicate that the increased glucose supply to the mammary gland in bGHRF-and bGH-treated cows does not result from changes in amounts of glucose transporter in the mammary cells, although bGHRF increased the amount of GLUT1 mRNA. This is consistent with the observation that bGH does not alter extraction rates of glucose in lactating mammary gland (McDowell et al., 1987; Davis et al., 1988a; Miller et al., 1991) .
Influence of bGH and bGHRF on GLUT4 mRNA in Skeletal Muscle and Omental Fat
Administration of bGH decreased ( P < .03) GLUT4 mRNA by 44% in skeletal muscle (Pectoralis prefun- Figure 3 . Northern blot analysis of insulin-responsive glucose transporter (GLUT4) mRNA from skeletal muscle of bovine growth hormone (bGH)-and bovine growth hormone-releasing factor (bGHRF)-treated cows and control cows. GH = RNA from bGH-treated cows; CTRL = RNA from control cows; GHRF = RNA from bGHRF-treated cows. The autoradiogram was exposed for 18 h. Figure 4 . Northern blot analysis of insulin-responsive glucose transporter (GLUT4) mRNA from omental fat of bovine growth hormone (bGH)-and bovine growth hormone-releasing factor (bGHRF)-treated cows and control cows. GH = RNA from bGH-treated cows; CTRL = RNA from control cows; GHRF = RNA from bGHRFtreated cows. The autoradiogram was exposed for 25 h. dis), but the effect of bGHRF was not significant (Figure 3 ; Table 1 ). The GLUT4 mRNA was barely detectable in the omental fat of control cows, but it became undetectable in bGH-and bGHRF-treated cows (Figure 4) . Our results are consistent with data on the effects of GH on amounts of glucose transporter protein in rat adipocyte plasma membrane (Kilgour et al., 1993) and the effects of porcine GH on amounts of GLUT4 mRNA and protein in pig adipose tissue and skeletal muscle, in which there were 20 to 65% decreases in mRNA and 30 to 40% decreases in GLUT4 protein (Etherton and Louveau, 1992; Liu et al., 1992) . In skeletal muscle and fat, glucose transport regulates glucose utilization (Crofford and Renold, 1965; Berger et al., 1975) . Thus, bGH and bGHRF may decrease glucose utilization in skeletal muscle and fat by decreasing glucose transporter expression in these tissues. The physiological impact of these effects may be to shift glucose from these tissues toward the mammary gland.
The effects of GH on adipocytes and muscle are known to be acute insulin-like and chronic antiinsulin-like effects (Davidson, 1987) . Insulin-like activities occur soon after the tissue is exposed to GH and include increased glucose uptake and utilization as well as antilipolysis. In this case, GH rapidly stimulates translocation of GLUT1 and GLUT4 proteins from a low-density microsomal fraction to the plasma membrane (Tanner et al., 1992) . The physiological significance of these insulin-like effects is uncertain. The anti-insulin-like effects of GH in intact animals can be seen within several hours after the first injection and after daily injections. The effects include inhibiting glucose uptake and glucose utilization, producing insulin resistance, and stimulating lipolysis (Davidson, 1987) . Results from the present study indicate that the decreased glucose transporter expression in muscle and fat tissues is involved in the anti-insulin effect of GH. The GLUT4 transporter is the predominant form of glucose transporter expressed in skeletal muscle and omental fat (Zhao et al., 1993; Zhao and Kennelly, unpublished observations) . Its expression and translocation is regulated by insulin in intact animals (Kahn, 1992) . Because the concentration of insulin was not changed in the serum of bGHRF-treated cows and increased in the serum of bGH-treated cows in the present study , GH and GHRF administration seems to impair the ability of insulin to stimulate glucose transporter expression and to suppress transporter expression. The intracellular GH signaling pathway may impede the insulin signaling pathway(s). It is also possible that GH acts directly (e.g., via GH response elements in the GLUT4 gene). For example, a GH response element has been identified in the serine protease inhibitor (Spi) 2.1 gene in rat liver (Yoon et al., 1990) .
Role of bGH and bGHRF in Nutrient Utilization and Partitioning
Glucose is the major precursor for lactose synthesis. Because lactose draws water osmotically into the milk, the rate of lactose synthesis is considered to be an important factor in the control of milk yield (Neville et al., 1983) . The exposure of Golgi membrane vesicles to varying concentrations of glucose indicated that, apart from inhibition at high concentration, the rates of lactose synthesis follow classical Michaelis-Menten kinetics with a K m of 1.5 mM (Kuhn et al., 1980) , which exceeds the glucose concentration within the cell. Thus, the intracellular glucose concentration may be a critical factor determining the rate of lactose synthesis and milk secretion. Because there is a steep concentration gradient of glucose across the plasma membrane, from 3.0 to 3.5 mM in plasma to .1 to .3 mM in the cell (Faulkner et al., 1981) , the transport of glucose across the plasma membrane may be the rate-limiting step. Tracer studies have shown a linear relationship between the rate of glucose transport and milk yield in cows (Kronfeld, 1982) . In the lactating mammary gland, the transport of glucose is mainly mediated by the facilitative glucose transporter GLUT1 (Madon et al., 1990; Zhao et al., 1993; . Results of the current study indicate that bGH and bGHRF do not alter the amount of GLUT1 in mammary cells.
Because previous data also indicate that bGH does not change plasma glucose concentration in lactating cows , the primary action of bGH in increasing mammary glucose availability may result from increased blood flow rate to the mammary gland (McDowell et al., 1987; Davis et al., 1988b ) and decreased glucose utilization as an energy source or glycerol moiety for triacylglycerol synthesis . Mammary blood flow has been correlated to milk yield; 400 to 500 L of blood pass through the mammary gland for each liter of cow or goat milk produced (Linzell, 1974) . The K m of GLUT1 has been reported to range from 2 to 20 mM (Kahn, 1992) . If bovine GLUT1 has a similar K m for glucose, the physiological blood glucose concentration (3.0 to 3.5 mM) should not saturate GLUT1. Thus, increased blood flow would enhance glucose uptake by GLUT1.
The control mechanisms involved in regulating mammary blood flow and milk synthesis in response to bGH treatment are unknown. Direct action of bGH on the bovine mammary gland during lactation has been discounted because of the failure to identify specific GH receptors in mammary tissue (Kazmer et al., 1986; Keys and Djiane, 1988) , although GH receptor mRNA is present in mammary tissue (Glimm et al., 1990 ). An alternative to direct action of bGH at the mammary gland is an indirect mediation of bGH action by IGF-I. Increased GH is associated with increased liver secretion of IGF-I (Gluckman et al., 1987) . Intra-arterial infusion of IGF-I into the goat mammary gland increased mammary blood flow and milk secretion (Prosser et al,. 1990 ). However, IGF-I did not replace GH in maintaining GLUT1 expression in the lactating rat mammary gland (Fawcett et al., 1992) . Thus, GH effects on milk production are not mediated solely through IGF-I.
The amount of GLUT1 mRNA was greater ( P < .02) in mammary glands from cows treated with bGHRF than in mammary glands from those treated with bGH ( Figure 1 ; Table 1 ). In contrast, bGH, but not bGHRF, significantly decreased ( P < .05) GLUT4 mRNA in the skeletal muscle (Figure 3 ; Table 1 ). A differential response to bGH and bGHRF treatment in glucose transporter gene expression has also been reported for liver and kidney . Because both groups had a similar serum GH concentration Vanderkooi et al., 1995) , the difference in the effect of bGHRF and bGH on glucose transporter mRNA expression in bovine tissues indicates that the galactopoietic action of bGHRF may not be mediated solely through GH. This view is supported by data from other studies. Dahl et al. (1993) reported that bGHRF-treated cows had approximately 10% greater milk yield than bGHtreated cows, although bGH and bGHRF resulted in similar concentrations of serum GH and IGF-I. In addition, milk yield decreased more slowly after withdrawal of bGHRF than after withdrawal of bGH (Hart et al., 1985; Dahl et al., 1993) . Growth hormone-releasing factor, initially isolated from a pancreatic tumor (Rivier et al., 1982) , stimulates insulin secretion from rat pancreatic islet cells in vitro (Green et al., 1990) and can also bind to vasoactive intestinal polypeptide receptors and stimulate adenylate cyclase activity in intestinal epithelial cells (Laburthe et al., 1983) . Thus, a direct action of GHRF on the gastrointestinal tract, liver, or mammary gland cannot be discounted.
There is an increasing body of data to support the hypothesis that the galactopoietic response of exogenous GH and GHRF is strongly influenced by their ability to direct nutrient partitioning and(or) utilization in various tissues (Bauman and Vernon, 1993) . In adipose tissues, GH decreases glucose uptake, inhibiting lipogenesis and stimulating lipolysis. The combination of decreased lipogenesis and increased lipolysis contributes to decreased body stores and increased concentrations of NEFA and glycerol in the blood Cisse et al., 1991; Dahl et al., 1993) . Peripheral tissues can then use NEFA as an alternative energy source to glucose (Peel et al., 1982; Tyrrell et al., 1988) , and the liver can use glycerol for increased gluconeogenesis . Growth hormone treatment also decreases glucose uptake in muscle (McDowell et al., 1987) . The overall effects are more glucose being available to the mammary gland and the mammary gland can increase glucose uptake (Davis et al., 1988a; Fullerton et al., 1989) . The mammary gland can also use NEFA as precursors for the synthesis of milk fat (Hart, 1988) , which also spares glucose and results in greater availability of glucose for lactose synthesis during GH treatment. The results presented here provide cellular evidence for this hypothesis.
In summary, the results of the present study provide insights into the physiological action of exogenous GH and GHRF in lactating cows. Evidence was obtained for effects of GH and GHRF on nutrient repartitioning and(or) utilization in the bovine; GH and GHRF may increase the supply of glucose for mammary metabolism by decreasing glucose transporter expression in muscle and fat tissues.
Implications
The expression of glucose transporter in skeletal muscle and adipose tissue was altered in response to bovine growth hormone (bGH) and bovine growth hormone-releasing factor (bGHRF). These changes are consistent with a reduction in glucose utilization by peripheral tissues and increased glucose supply to the mammary gland in response to bGH and bGHRF treatment.
